Massive Weight Gain and Hostility Force Mirtazapine Stoppage
Dear Editor:
Mirtazapine is a novel antidepressant with a mechanism that involves enhancing serotonergic and noradrenergic neurotransmission via blockade of alpha-2 adrenergic autoreceptors and heteroreceptors. Because of its unique pharmacologic profile, it is devoid of anticholinergic-, adrenergic-, and serotonin-related side effects (1) . The most frequently reported side effects are mild and transient sedation and weight gain (1, 2) . Others have found it to have substantially better tolerability than the serotonergic or tricyclic antidepressants (3, 4) . I report the case of a patient who stopped mirtazapine after severe and unusual side effects.
Case Report
Ms KD is a 40-year-old nurse with a long history of unipolar depression that resulted in several hospitalizations and several antidepressant trials, including electroconvulsive therapy. During one such episode, her depression was treated unsuccessfully with adequate trials of citalopram, venlafaxine, paroxetine, and bupropion. After a washout period of about 10 days, Ms KD was started on 15 mg of mirtazapine given at bedtime. After a week, this was increased to 30 mg. She also took 0.5 mg of lorazepam up to twice daily. She remained depressed, became irritable, and noticed significant and sudden weight gain. At lower dosages, mirtazepine acts as an antihistamine and enhances sertononergic transmission, which favours weight gain (4) . Therefore, the dosage was increased to 45 mg daily to recruit and enhance noradrenergic release, with the hope of controlling her weight. Over a 6-week period, she gained more than 40 lb. The weight gain was associated with swelling of her hands, legs, feet, and eyelids. She became incapacitated because the swelling prevented grasping and turning faucets, and she became unable to get in and out of the bathtub. Climbing stairs became impossible, and she needed help with most activities. Ms KD also became extremely anxious and very hostile, especially toward her 2 children. She became fearful at night and asked her husband to be close to her, preventing him from watching television. All these new problems-and especially her hatred of her own children-frightened her, and she requested that mirtazapine be discontinued. Shortly thereafter her hostility and fear subsided, the edema resolved, and her weight gradually returned to baseline. Subsequently, she has been doing well on clomipramine.
Even though mirtazapine has been reported to be well tolerated and to have potential value as a treatment for anxiety disorders (5, 6) , my patient became more anxious and hostile. The weight gain of 40 lb was also much higher than reported in the literature. This case underlines the need for clinicians to be alert to the possibility of severe idiosyncratic adverse events in patients starting newer products.
G Abraham, MD, FRCPC Kingston, Ontario

Functional Dyspepsia and Mirtazapine
Functional dyspepsia (FD), also known as nonulcer dyspepsia or dyspepsia of unknown cause, refers to a complex of symptoms characterized by pain or discomfort and bloating centred in the upper abdomen, early satiety, fullness, and nausea. These upper gastrointestinal symptoms are not associated with any structural abnormality demonstrable by standard diagnostic investigations (that is, radiological, endoscopic, and histological). There is no evidence that dyspepsia is exclusively relieved by defecation or associated with the onset of a change in stool frequency or stool form (1) . FD is one of the most common clinical problems in medical outpatients and is associated with considerable health and economic burden (2) . The available literature reports that FD is associated with a higher lifetime prevalence of psychiatric illness, predominantly anxiety and depressive disorders (3, 4) . I report the efficacy of mirtazapine in treating a patient with FD and depression.
Case Report
Ms A, a 54-year-old married woman with epigastric discomfort, fullness, nausea, and postprandial bloating, was referred for what her gastroenterologist had diagnosed as FD according to Rome II criteria (5) . The FD symptoms had been present episodically for the last 5 years and had been virtually unremitting for the last 6 months. The results of extensive medical evaluation, including esophageal manometry, 24-hour ambulatory intraesophageal pH monitoring, and electrogastrography, were negative. Her gastroenterologist had treated her with valium 2 mg 3 times daily and cisapride 10 mg 3 times daily, with minimal improvement.
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